Market Overview

ICYMI: Snapchat, Molecular Biotech's CEO Speaks, SEC Examines Crypto ICOs


In case you missed it, here are some of Benzinga's top stories from Thursday, March 1, 2018.

SEC Probes Crypto

With headlines that briefly sent bitcoin and other digital currencies falling, the Wall Street Journal reported the SEC is investigating companies and advisers in the cryptocurrency space. Wayne Duggan alerted readers to stocks the Street seemed to think were most exposed, in “6 Stocks Moving On News Of SEC’s Crypto Probe.”

Related Link: Overstock Falls As SEC Probes 'Dozens' Of Companies Involved With Cryptocurrencies

Snapchat Update Filtering Out Users?

Snap Inc (NYSE: SNAP) continues to take criticism from all sides regarding its recent update to the Snapchat platform, but Stifel analysts highlighted data that seems to confirm concerns the changes are leading to lower user engagement. Jayson Derrick reports.

Moleculin Biotech And The ‘Remarkable’ Leukemia Treatment Candidate

Moleculin Biotech Inc (NASDAQ: MBRX) is hoping to succeed by forging a path where other biotechs fear to tread - rare and hard to treat diseases. Learn more from an exclusive conversation with the company’s CEO, in Elizabeth Balboa’s “Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'.”

Posted-In: Analyst Color Biotech Cryptocurrency Previews After-Hours Center Markets Trading Ideas Interview


Related Articles (MBRX + OSTK)

View Comments and Join the Discussion!

Latest Ratings

DRIBank of AmericaReiterates130.0
PVACNorthland SecuritiesUpgrades0.0
NKEWells FargoMaintains80.0
DRIWells FargoMaintains120.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Vetr Crowd Downgrades Micron, But Remains Bullish

Investors May Have To Wait Further For L Brands Recovery